AKTS
Aktis OncologyยทNASDAQ
--
--(--)
--
--(--)
AKTS Profile
Aktis Oncology, Inc.
A clinical-stage oncology company
17 Drydock Avenue
Suite 17-401
Boston
Massachusetts 02210
--
Aktis Oncology, Inc. was incorporated under the laws of the State of Delaware in August 2020. The company is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to a large patient population, including those unresolved by existing platform technologies. The company's vision is to redefine cancer therapy, and the company is advancing a proprietary micro-protein radioactive coupling platform designed to deliver radioisotopes directly to tumors, enhancing therapeutic effects while minimizing systemic radiation exposure. Aktis Oncology's pilot program is targeting Nectin-4 and is currently in clinical development for locally advanced or metastatic urothelial carcinoma and other solid tumors. The company has leveraged its expertise in radiopharmaceutical development and supply chain management to create a portfolio of innovative therapeutic drug candidates designed to address multiple tumor types that are not adequately targeted by current therapies.
